New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
BD (NYSE: BDX) announced new data highlighting the effectiveness of its artificial intelligence technology in detecting controlled substance diversion in hospital operating rooms. A study conducted at an Ochsner Health medical center, published in the American Journal of Health-System Pharmacy, showed that BD HealthSight™ Diversion Management software can identify blind spots in medication movement undetected by manual processes.
Key findings include:
- 55% increase in charting discrepancies detected
- 14% increase in incidents resolved by operating room analysts
- 10% decrease in cases requiring additional documentation
- Reduction in auditor review time from 3 business days to 50 minutes
The study emphasizes the importance of advanced analytics in combating drug diversion, a persistent issue in healthcare settings.
BD (NYSE: BDX) ha annunciato nuovi dati che evidenziano l'efficacia della sua tecnologia di intelligenza artificiale nella rilevazione della diversion di sostanze controllate nelle sale operatorie degli ospedali. Uno studio condotto presso un centro medico Ochsner Health, pubblicato nell'American Journal of Health-System Pharmacy, ha dimostrato che il software BD HealthSight™ Diversion Management può identificare le aree cieche nel movimento dei farmaci che non vengono rilevate dai processi manuali.
I risultati chiave includono:
- Aumento del 55% delle discrepanze nel tracciamento rilevate
- Aumento del 14% degli incidenti risolti dagli analisti delle sale operatorie
- Riduzione del 10% dei casi che necessitano di documentazione aggiuntiva
- Riduzione del tempo di revisione degli auditor da 3 giorni lavorativi a 50 minuti
Lo studio sottolinea l'importanza delle analisi avanzate nella lotta contro la diversion di farmaci, un problema persistente negli ambienti sanitari.
BD (NYSE: BDX) anunció nuevos datos que destacan la efectividad de su tecnología de inteligencia artificial en la detección de la desviación de sustancias controladas en las salas de operaciones de los hospitales. Un estudio realizado en un centro médico Ochsner Health, publicado en el American Journal of Health-System Pharmacy, mostró que el software BD HealthSight™ Diversion Management puede identificar puntos ciegos en el movimiento de medicamentos que no son detectados por procesos manuales.
Los hallazgos clave incluyen:
- Aumento del 55% en las discrepancias de registro detectadas
- Aumento del 14% en los incidentes resueltos por analistas de sala de operaciones
- Reducción del 10% en los casos que requieren documentación adicional
- Reducción en el tiempo de revisión de auditoría de 3 días hábiles a 50 minutos
El estudio enfatiza la importancia de las analíticas avanzadas en la lucha contra la desviación de medicamentos, un problema persistente en los entornos de atención médica.
BD (NYSE: BDX)는 병원 수술실에서 통제 물질의 전환을 감지하는 데 있어 인공지능 기술의 효과를 강조하는 새로운 데이터를 발표했습니다. Ochsner Health 의료 센터에서 수행된 연구는 미국 건강 시스템 약국 저널에 발표되었으며, BD HealthSight™ 전환 관리 소프트웨어가 수동 프로세스에서 감지되지 않는 약물 이동의 맹점을 식별할 수 있음을 보여주었습니다.
주요 결과는 다음과 같습니다:
- 감지된 기록상의 불일치 증가 55%
- 수술실 분석가에 의해 해결된 사건 증가 14%
- 추가 문서화를 요구하는 사례 감소 10%
- 감사 검토 시간 감소: 3일에서 50분으로 단축
이 연구는 의료 환경에서 지속적으로 발생하는 약물 전환 문제에 대응하기 위해 고급 분석의 중요성을 강조합니다.
BD (NYSE: BDX) a annoncé de nouvelles données soulignant l'efficacité de sa technologie d'intelligence artificielle pour détecter la déviation des substances contrôlées dans les salles d'opération des hôpitaux. Une étude réalisée dans un centre médical Ochsner Health, publiée dans l'American Journal of Health-System Pharmacy, a montré que le logiciel BD HealthSight™ Diversion Management peut identifier des zones d'ombre dans le mouvement des médicaments, indétectables par des processus manuels.
Les résultats clés incluent :
- Augmentation de 55 % des écarts de comptabilité détectés
- Augmentation de 14 % des incidents résolus par les analystes de salle d'opération
- Diminution de 10 % des cas nécessitant une documentation supplémentaire
- Réduction du temps d'examen des auditeurs de 3 jours ouvrables à 50 minutes
L'étude souligne l'importance de l'analyse avancée dans la lutte contre la déviation de médicaments, un problème persistant dans les environnements de soins de santé.
BD (NYSE: BDX) hat neue Daten veröffentlicht, die die Wirksamkeit seiner Künstlichen Intelligenz-Technologie bei der Erkennung von Abweichungen bei kontrollierten Substanzen in den Operationssälen von Krankenhäusern hervorheben. Eine Studie, die in einem Ochsner Health Medizinzentrum durchgeführt und im American Journal of Health-System Pharmacy veröffentlicht wurde, zeigte, dass die BD HealthSight™ Diversion Management Software blinde Flecken im Medikamentenfluss identifizieren kann, die von manuellen Prozessen nicht erkannt werden.
Wichtige Ergebnisse umfassen:
- 55%ige Zunahme bei den entdeckten Dokumentationsabweichungen
- 14%ige Zunahme bei den Vorfällen, die von Operationsanalysten gelöst wurden
- 10%ige Abnahme der Fälle, die zusätzliche Dokumentation erforderten
- Verringerung der Prüfdauer von 3 Arbeitstagen auf 50 Minuten
Die Studie betont die Bedeutung von fortschrittlicher Analytik im Kampf gegen Drogenabzweigung, ein anhaltendes Problem in der Gesundheitsversorgung.
- BD's AI technology showed a 55% increase in detecting charting discrepancies related to drug diversion
- The software improved efficiency with a 14% increase in incidents resolved by operating room analysts
- Cases requiring additional documentation decreased by 10%
- Auditor review time for potential diversion cases reduced from 3 business days to 50 minutes
- None.
Insights
This study highlights the significant impact of BD's AI-powered HealthSight Diversion Management software in detecting controlled substance diversion in hospital settings. The 55% increase in charting discrepancies identified and the 14% improvement in incident resolution efficiency are substantial improvements.
The reduction in case review time from three days to just 50 minutes is particularly noteworthy, as it allows for quicker intervention and potentially prevents further diversion. This technology addresses a critical blind spot in operating room medication management, where drug diversion risks are highest.
For investors, this development positions BD favorably in the growing market for health care compliance and safety solutions. The software's ability to enhance efficiency while improving detection rates could lead to increased adoption across health systems, potentially driving revenue growth in BD's digital health segment.
However, it's important to note that while the technology shows promise, widespread adoption may face challenges such as implementation costs and potential resistance to change in established hospital processes. The long-term impact on BD's financials will depend on market penetration and the company's ability to demonstrate consistent ROI for health systems.
The implementation of BD's AI-driven diversion management software represents a significant advancement in addressing the "hidden epidemic" of hospital drug diversion. This technology not only enhances detection capabilities but also streamlines the investigation process, which is important for maintaining regulatory compliance and patient safety.
From a compliance perspective, the software's ability to track a broader range of discrepancies, including whole dose waste and cancelled transactions, fills critical gaps in existing manual processes. This comprehensive approach aligns with increasing regulatory scrutiny on controlled substance management in healthcare settings.
The efficiency gains reported, such as the 10% decrease in cases requiring additional provider documentation, suggest potential cost savings and reduced administrative burden for healthcare facilities. This could be a strong selling point for BD, particularly among larger health systems struggling with complex medication management across multiple sites.
While the study results are promising, it's important to consider that this represents data from a single Ochsner Health facility. Broader studies across diverse healthcare settings will be necessary to fully validate the software's effectiveness and generalizability. Nevertheless, this innovation positions BD as a leader in addressing a persistent and serious healthcare challenge.
Hospital drug diversion occurs when a health care worker "diverts" opioids or other controlled substances away from patients for personal use or sale. The operating room is one of the highest risk areas for the diversion of controlled substances, such as narcotics used for anesthesia and pain management.
A new research study1 conducted at an Ochsner Health medical center and published in the American Journal of Health-System Pharmacy (AJHP) shows how the use of artificial intelligence in BD HealthSightTM Diversion Management software can help highlight blind spots about the movement of medication in the operating room that are undetected by current manual processes. This system uses artificial intelligence and advanced analytics to provide a deep level of connectivity and visibility into the behaviors of individuals interacting with medication storage, management and pharmacy systems, which is a critical need for large, complex health systems with hundreds of points of controlled substance dispensing across multiple sites.
"In health care, where patient care is crucial, being able to spot potential issues like drug diversion is not only important but a moral duty," said Alexandre P. Raymond, PharmD, MS, director for Drug Diversion Prevention & Response, Compliance at Ochsner Health. "The results of our research study underscore the transformative power of advanced analytics software, powered by machine-learning algorithms, in helping health systems not only meet their goals but also drive tangible value. This technology equips health care providers with the tools needed to safeguard patients, uphold integrity and combat drug diversion effectively."
Study Highlights
After implementing BD HealthSightTM Diversion Management software, the Ochsner facility observed a
The study also highlighted efficiency improvements in the facility's efforts to reconcile incidents of potential drug diversion in the operating room. Despite the increase in the volume of charting discrepancies, the percentage of incidents that were able to be resolved by the operating room analyst increased by
The study measured the facility's ability to identify, reconcile and investigate potential incidents of drug diversion across their 34 operating rooms where more than 55,000 surgeries are performed and more than 100,000 doses of controlled substances are dispensed annually.
Finding Solutions to Health Care's "Hidden Epidemic"
In 2019, BD issued a report, Health Care's Hidden Epidemic: A Call to Action on Hospital Drug Diversion2, based on a national survey that examined drug diversion in
This new study data builds on the 2019 report and illustrates that drug diversion remains a significant issue and that there is an opportunity for advancements in technology to provide solutions to identifying and investigating incidents of potential drug diversion.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Hallie Nicholson | Adam Reiffe |
BD Corporate Communications | BD Investor Relations |
619.614.6251 | 201.847.6927 |
1 https://academic.oup.com/ajhp/article-abstract/81/11/e322/7624294
2 https://go.bd.com/BD-Institute-for-Medication-Management-Excellence-Drug-Diversion.html
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-data-reveals-bds-artificial-intelligence-software-highly-effective-in-detecting-indicators-of-controlled-substance-diversion-302259346.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What is the effectiveness of BD's AI software in detecting drug diversion?
How did BD's software impact the efficiency of investigating potential drug diversion cases?
Where was the study on BD's AI software for drug diversion detection conducted?
What specific improvements did BD's HealthSight™ Diversion Management software bring to drug diversion detection?
